DENVER, Colo. (247marketnews.com) — Universe Pharmaceuticals (NASDAQ:UPC) announced that it has entered into a share purchase agreement to acquire Best Praise International Limited, a transaction that would add five China-based pharmaceutical patents to the company’s intellectual property portfolio. The proposed acquisition, valued at approximately US$10.75 million and payable in Class A ordinary shares, is expected to broaden the company’s research and development platform while expanding its focus beyond its existing traditional Chinese medicine business.
According to the company, the patent portfolio includes technologies related to age-related diseases, neurodegenerative conditions, cognitive disorders, cardiovascular pharmaceutical applications, antibacterial compounds, and drug delivery systems. Management believes these assets complement Universe Pharmaceuticals’ emphasis on elderly healthcare and may create future opportunities for research collaborations, licensing arrangements, co-development initiatives, and commercialization efforts. The transaction has been approved by the company’s board of directors and is expected to close during the third quarter of 2026, subject to customary closing conditions.
Universe Pharmaceuticals also stated that the acquisition is intended to strengthen its long-term asset base while supporting expansion of its pharmaceutical development capabilities. The company indicated that adding intellectual property assets may enhance its product pipeline and provide additional avenues for future growth. Investors should note, however, that the transaction remains subject to closing conditions, and there can be no assurance it will be completed on the anticipated timeline or at all.
Headquartered in Jiangxi Province, China, Universe Pharmaceuticals manufactures and distributes traditional Chinese medicine derivatives, biomedical drugs, medical devices, traditional Chinese medicine pieces, and dietary supplements. Its products are currently marketed across 30 provinces in China. As the company seeks to expand its intellectual property portfolio, investors will likely monitor the progress of the acquisition and any subsequent research, licensing, or commercialization developments arising from the newly acquired patents.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.;